Kognitive Funktionsstörungen unter Systemtherapie bei metastasiertem Melanom

Translated title of the contribution: Immunological mechanisms of cognitive dysfunction under systemic therapy in metastatic melanoma

Miriam Mengoni, Thomas Tüting, Evelyn Gaffal*

*Corresponding author for this work

Abstract

Neurocognitive impairments of memory, speech, and attention can occur in cancer patients as a direct result of the cancer but also in the context of therapy. With the development of modern immunotherapies and their use in combination with surgery and radiation therapy, the number of long-term survivors has significantly increased. As a result, detrimental effects on brain function and structure in cancer patients not only during treatment but also after completion of therapy have become a key issue in clinical oncology. Early diagnosis and treatment of neurocognitive disorders is of great importance for quality of life, therapy adherence, and overall survival of the affected patients. In this review, we discuss the underlying mechanisms with a special focus on metastatic melanoma. Furthermore, practice-relevant diagnostics, prophylaxis, and intervention options are discussed.

Translated title of the contributionImmunological mechanisms of cognitive dysfunction under systemic therapy in metastatic melanoma
Original languageGerman
JournalDermatologie
Volume73
Issue number12
Pages (from-to)937-942
Number of pages6
ISSN2731-7005
DOIs
Publication statusPublished - 12.2022

Fingerprint

Dive into the research topics of 'Immunological mechanisms of cognitive dysfunction under systemic therapy in metastatic melanoma'. Together they form a unique fingerprint.

Cite this